SCHEMBL1476755

SCHEMBL1476755

C[SiH](C)OC(c1cc(Nc2ncc(Br)n3ncnc23)ccc1N1CCOCC1)C(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPKAPK5 Q8IW41 4/20 0.41
MAPT P10636 2/20 0.34
MAPK1 P28482 1/20 0.34
AHR P35869 1/20 0.34
HTT P42858 1/20 0.34
EGFR P00533 1/20 0.34
SYK P43405 1/20 0.33
HPGD P15428 1/20 0.33
IGF1R P08069 2/20 0.32
TSHR P16473 1/20 0.32
NR4A1 P22736 1/20 0.32
FYN P06241 1/20 0.32
BRD4 O60885 1/20 0.32
PIK3CA P42336 1/20 0.32
MAPK9 P45984 1/20 0.32
MAPK10 P53779 1/20 0.32
ERBB2 P04626 2/20 0.31
HTR2C P28335 1/20 0.31
HSD17B10 Q99714 1/20 0.31
AURKA O14965 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1674279 0.86 FYN (0.44) MAPKAPK5SYKIGF1RFYNAURKA
SCHEMBL1477664 0.78 MAPKAPK5 (0.47) MAPKAPK5MAPTMAPK1AHRHTT
SCHEMBL1476757 0.77 MAPKAPK5 (0.42) MAPKAPK5MAPTMAPK1AHRHTT
SCHEMBL1476759 0.77 MAPKAPK5 (0.42) MAPKAPK5MAPTMAPK1AHRHTT
SCHEMBL1476134 0.75 MAPKAPK5 (0.45) MAPKAPK5MAPTMAPK1AHRHTT
SCHEMBL1476085 0.74 MAPKAPK5 (0.64) MAPKAPK5MAPTMAPK1AHRHTT
SCHEMBL1475718 0.74 SYK (0.48) MAPKAPK5SYKMAPK9MAPK10
SCHEMBL1476927 0.71 MAPKAPK5 (0.50) MAPKAPK5MAPTHTTIGF1R
SCHEMBL1475839 0.69 TRPV1 (0.39) MAPKAPK5BRD4AURKA
SCHEMBL1476881 0.68 MAPKAPK5 (0.48) MAPKAPK5MAPTMAPK1AHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110178067-A1 TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES ANDREWS MARTIN JAMES INGLIS 2011-07-21 US disclosed
US-7915256-B2 Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2011-03-29 US disclosed
US-20100298300-A1 TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES ANDREWS MARTIN JAMES INGLIS 2010-11-25 US disclosed
EP-2029602-B1 TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES GALAPAGOS NV (BE) 2010-04-21 EP disclosed
US-7501411-B2 Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS, NV (BE) 2009-03-10 US disclosed
US-20080090818-A1 Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases GALAPAGOS NV (BE) 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178067-A1 TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES PTGES, IL1B, PTGER1 MAPKAPK5 5/4885MAPT 647/4885MAPK1 324/4885
US-20100298300-A1 TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES P2RX5, P2RX3, IL1B MAPKAPK5 18/4885MAPT 438/4885MAPK1 567/4885
US-20080090818-A1 Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases P2RX5, P2RX3, IL1B MAPKAPK5 18/4885MAPT 438/4885MAPK1 567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.